Patient Selection for New nAMD and DME Therapies
Peter Kaiser, MD discusses the utilization of newer agents, faricimab and high dose aflibercept, for refractory patients who haven't responded well to previous treatments and for patients doing well but aiming to extend dosing intervals.
Summary
In the provided transcript, the physicians discuss the use of newer agents, such as faricimab and high-dose aflibercept, in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). They mention that these agents were primarily tested in treatment-naive patients but are also being used in refractory patients who have not responded well to other anti-VEGF treatments. The physicians describe two main scenarios for using these agents: switching patients who are not doing well on their current treatment to a newer agent and attempting to further extend treatment intervals in patients who are responding well but still require frequent injections. They emphasize the importance of individualized treatment approaches and monitoring patient response closely. Additionally, they discuss their experiences with different treatment strategies, including switching between agents and adjusting dosing intervals, based on patient needs and response. The physicians also touch upon the safety profile of these newer agents, highlighting the need for vigilance, especially in the case of brolucizumab, and expressing confidence in the safety of faricimab and high-dose aflibercept based on clinical trial data.
This summary was AI-generated and edited for clarity.
